Canine hemangiosarcoma has an aggressive biological behavior, with less than 10% of dogs being alive at 12 months. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to the traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Sixteen dogs were enrolled; following staging work-up 9 were treated with AC and 7 with ADTIC. Dogs treated with ADTIC tended to have a longer TTM (p=0.094) compared to the dogs treated with AC (365 versus 90 days) and to survive longer (p=0.066; 480 versus 90 days). Both protocols were well tolerated, with no need for dose reduction or increased interval between treatments. ADTIC was well tolerated and seemed to prolong TTM and survival time in dogs with biologically aggressive hemangiosarcoma, especially if not metastatic at presentation.
Beatrice L, Finotello R, Stefanello D, Zini E, Bettini G, Poli A, et al. (2011). Confronto fra due diversi protocolli a base di doxorurubicina per il trattamento adiuvante dell’emangiosarcoma a sede biologicamente maligna del cane.. CREMONA : SCIVAC.
Confronto fra due diversi protocolli a base di doxorurubicina per il trattamento adiuvante dell’emangiosarcoma a sede biologicamente maligna del cane.
BETTINI, GIULIANO;Marconato L.
2011
Abstract
Canine hemangiosarcoma has an aggressive biological behavior, with less than 10% of dogs being alive at 12 months. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to the traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Sixteen dogs were enrolled; following staging work-up 9 were treated with AC and 7 with ADTIC. Dogs treated with ADTIC tended to have a longer TTM (p=0.094) compared to the dogs treated with AC (365 versus 90 days) and to survive longer (p=0.066; 480 versus 90 days). Both protocols were well tolerated, with no need for dose reduction or increased interval between treatments. ADTIC was well tolerated and seemed to prolong TTM and survival time in dogs with biologically aggressive hemangiosarcoma, especially if not metastatic at presentation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
